^
Association details:
Biomarker:SP140 overexpression
Cancer:Melanoma
Drug Class:CTLA4 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response

Published date:
12/13/2022
Excerpt:
Examining the dataset of metastatic melanoma patients who underwent CTLA-4 blockade immunotherapy, we found significantly more favorable survival in patients who had high SP140 levels (n=12) than in patients with low levels of SP140 (n=28) (log-rank test, p=4.98E-3).
DOI:
10.1136/jitc-2022-005088